📌Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use https://t.co/FsT2UiXY3j
4/ The team at Stanford did an amazing job of helping Jenya get back on her feet and after diagnosis she was prescribed a special medication called Eculizumab that she will need to take for the unforeseeable future, possibly the rest of her life. https:/
@Mkey27 Agree. It is important to define who will benefit from long-term continuation in order to minimize drug and financial toxicity. This paper (from CAREiHUS) discusses strategies to restrict use when possible https://t.co/TqvWDP4L8z
RT @farma_gregorio: Eculizumab en SUHa: ¿hasta cuándo continuamos el tratamiento? Diferentes escenarios para restringir su uso. https://t.c…
RT @farma_gregorio: Eculizumab en SUHa: ¿hasta cuándo continuamos el tratamiento? Diferentes escenarios para restringir su uso. https://t.c…
RT @farma_gregorio: Eculizumab en SUHa: ¿hasta cuándo continuamos el tratamiento? Diferentes escenarios para restringir su uso. https://t.c…
RT @farma_gregorio: Eculizumab en SUHa: ¿hasta cuándo continuamos el tratamiento? Diferentes escenarios para restringir su uso. https://t.c…
RT @farma_gregorio: Eculizumab en SUHa: ¿hasta cuándo continuamos el tratamiento? Diferentes escenarios para restringir su uso. https://t.c…
RT @farma_gregorio: Eculizumab en SUHa: ¿hasta cuándo continuamos el tratamiento? Diferentes escenarios para restringir su uso. https://t.c…
RT @farma_gregorio: Eculizumab en SUHa: ¿hasta cuándo continuamos el tratamiento? Diferentes escenarios para restringir su uso. https://t.c…
RT @farma_gregorio: Eculizumab en SUHa: ¿hasta cuándo continuamos el tratamiento? Diferentes escenarios para restringir su uso. https://t.c…
RT @farma_gregorio: Eculizumab en SUHa: ¿hasta cuándo continuamos el tratamiento? Diferentes escenarios para restringir su uso. https://t.c…
RT @farma_gregorio: Eculizumab en SUHa: ¿hasta cuándo continuamos el tratamiento? Diferentes escenarios para restringir su uso. https://t.c…
RT @farma_gregorio: Eculizumab en SUHa: ¿hasta cuándo continuamos el tratamiento? Diferentes escenarios para restringir su uso. https://t.c…
RT @farma_gregorio: Eculizumab en SUHa: ¿hasta cuándo continuamos el tratamiento? Diferentes escenarios para restringir su uso. https://t.c…
RT @farma_gregorio: Eculizumab en SUHa: ¿hasta cuándo continuamos el tratamiento? Diferentes escenarios para restringir su uso. https://t.c…
RT @farma_gregorio: Eculizumab en SUHa: ¿hasta cuándo continuamos el tratamiento? Diferentes escenarios para restringir su uso. https://t.c…
RT @farma_gregorio: Eculizumab en SUHa: ¿hasta cuándo continuamos el tratamiento? Diferentes escenarios para restringir su uso. https://t.c…
RT @farma_gregorio: Eculizumab en SUHa: ¿hasta cuándo continuamos el tratamiento? Diferentes escenarios para restringir su uso. https://t.c…
Eculizumab en SUHa: ¿hasta cuándo continuamos el tratamiento? Diferentes escenarios para restringir su uso. https://t.co/6UMwJtQkKN https://t.co/tz6jIz28ET
RT aHUSAllianceAct Gain insight into 'The Dutch Approach' & the CUREiHUS study with this overview of the presentations and issues from the Nov 2018 International #aHUS Patient Symposium https://t.co/mnSkwzzhmx aHUSAllianceAct - Global atypical HUS col
Gain insight into 'The Dutch Approach' & the @CUREiHUS study with this overview of the presentations and issues from the Nov 2018 International #aHUS Patient Symposium https://t.co/cL8uP6KXTk @aHUSAllianceAct - Global atypical HUS collaboration partne
RT @EuRefNetwork: Strategies towards restrictive use of #Eculizumab in #aHUS https://t.co/eAfkeS0sA5
RT @EuRefNetwork: Strategies towards restrictive use of #Eculizumab in #aHUS https://t.co/eAfkeS0sA5
Strategies towards restrictive use of #Eculizumab in #aHUS https://t.co/eAfkeS0sA5
RT aHUSAllianceAct #Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use. https://t.co/m9pjHgD9ia radboudumc #aHUS #SHUa CUREiHUS #complement atypical HUS #PersonalizedMedicine https://t.co/aSAaT4Icuv
#Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use. https://t.co/Zs3wT4IOrY @radboudumc #aHUS #SHUa @CUREiHUS #complement atypical HUS #PersonalizedMedicine
RT @Ped_Neph: 🆕🆓 #OpenAccess 🔓 Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use https://t.co/B143133CBy…
RT aHUSAllianceAct RT aHUSCanada: New data from CUREiHUS combined with review of literature.Treating #aHUS patients with #eculizumab & strategies towards #PersonalizedMedicine. (link: https://t.co/m9pjHgD9ia) https://t.co/jJLBZllo1Y… https://t.co/rmSSV
RT @aHUSCanada: New data from @CUREiHUS combined with review of literature.Treating #aHUS patients with #eculizumab & strategies towards #P…
New data from @CUREiHUS combined with review of literature.Treating #aHUS patients with #eculizumab & strategies towards #PersonalizedMedicine. (link: https://t.co/DKCSVDmzMO) https://t.co/bNQUGwI93X…
RT @Ped_Neph: 🆕🆓 #OpenAccess 🔓 Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use https://t.co/B143133CBy…
RT @aHUSAllianceAct: #PersonalizedMedicine likely to affect #clinicalcare for atypical HUS: Data from team at @radboudumc on Dutch tailore…
RT @Ped_Neph: 🆕🆓 #OpenAccess 🔓 Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use https://t.co/B143133CBy…
RT aHUSAllianceAct #PersonalizedMedicine likely to affect #clinicalcare for atypical HUS: Data from team at radboudumc on Dutch tailored approach to #eculizumab. CUREiHUS study results: key points for the #aHUS space. #pharma #drug #complement … https://t
#PersonalizedMedicine likely to affect #clinicalcare for atypical HUS: Data from team at @radboudumc on Dutch tailored approach to #eculizumab. @CUREiHUS study results: key points for the #aHUS space. #pharma #drug #complement https://t.co/cL8uP6KXTk
RT @Ped_Neph: 🆕🆓 #OpenAccess 🔓 Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use https://t.co/B143133CBy…
🆕🆓 #OpenAccess 🔓 Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use https://t.co/B143133CBy @radboudumc #aHUS #Eculizumab #Pediatrics https://t.co/9Sj80sH0vn
RT @CUREiHUS: How to treat #aHUS patients with #eculizumab and strategies towards personalized medicine. See our review discussing all lite…
RT aHUSAllianceAct RT aHUSAmerica: Treating #aHUS patients w/ #eculizumab & strategies re #PersonalizedMedicine. New data from CUREiHUS combined w/ review of the literature. Atypical HUS #clinicalmedicine, tailored #complement therapy & data re #ge
RT @aHUSAmerica: Treating #aHUS patients w/ #eculizumab & strategies re #PersonalizedMedicine. New data from @CUREiHUS combined w/ review o…
RT @ASPNeph: Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use https://t.co/aTbDq8LnbQ @Ped_Neph #openacc…
Treating #aHUS patients w/ #eculizumab & strategies re #PersonalizedMedicine. New data from @CUREiHUS combined w/ review of the literature. Atypical HUS #clinicalmedicine, tailored #complement therapy & data re #genetics, kidney #transplantation, m
RT @aHUSAllianceAct: Once #aHUS patients are in remission, how do #clinicians proceed with disease management? New article raises important…
RT @ASPNeph: Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use https://t.co/aTbDq8LnbQ @Ped_Neph #openacc…
RT aHUSAllianceAct Dutch approach to #personalizedmedicine medicine: CUREiHUS study data for use of #eculizumab for atypical HUS. Photos from talks at int'l #aHUS patient symposium w/ radboudumc Research: https://t.co/m9pjHgD9ia Nicolevandekar aHUSUKvo… h
Dutch approach to #personalizedmedicine medicine: @CUREiHUS study data for use of #eculizumab for atypical HUS. Photos from talks at int'l #aHUS patient symposium w/ @radboudumc Research: https://t.co/Zs3wT4IOrY @Nicolevandekar @aHUSUKvoice @ahusindia #SH
RT aHUSAllianceAct New data re #aHUS treatment in Ped_Neph has potential to reshape #clinicalcare for the #raredisease atypical HUS re #eculizumab therapy. aHUSAllianceAct attends 9 Nov mtg with radboudumc team to learn more. sidsdoc CheckOrphan National…
New data re #aHUS treatment in @Ped_Neph has potential to reshape #clinicalcare for the #raredisease atypical HUS re #eculizumab therapy. @aHUSAllianceAct attends 9 Nov mtg with @radboudumc team to learn more. @sidsdoc @CheckOrphan @NationalaHUS #nephjc @I
How to treat #aHUS patients with #eculizumab and strategies towards personalized medicine. See our review discussing all literature https://t.co/teUdVVLA8v
RT @aHUSAllianceAct: Happening now: Leaders in atypical HUS patient organizations from multiple nations gather on 9 Nov in Nijmegen to dis…
Happening now: Leaders in atypical HUS patient organizations from multiple nations gather on 9 Nov in Nijmegen to discuss #aHUS research, issues & advancement re the #RareDisease aHUS. @Nicolevandekar @radboudumc https://t.co/Zs3wT4IOrY #nephrology
RT aHUSAllianceAct Once #aHUS patients are in remission, how do #clinicians proceed with disease management? New article raises important points – Optimal spacing & dosing? #Complement monitoring? #Eculizumab in atypical HUS: Strategies toward Restrict
Once #aHUS patients are in remission, how do #clinicians proceed with disease management? New article raises important points – Optimal spacing & dosing? #Complement monitoring? #Eculizumab in atypical HUS: Strategies toward Restrictive Use. https://t.
Eculizumab in atypical hemolytic uremic syndrome: strategies toward restrictive use https://t.co/aTbDq8LnbQ @Ped_Neph #openaccess #aHUS